Hot Medical Stocks To Invest In 2019

Planning for retirement generally means taking a close look at your personal needs and goals, as well as those of the person you’re married to. But when you and your spouse have a wide age gap, retirement planning can become a bit trickier. Not only are you less likely, in that scenario, to retire simultaneously, but there may also be consequences to one of you leaving the workforce well ahead of the other. Therefore, be sure to consider the following factors when you’re dealing with a significant age gap.

1. Health insurance

Medicare eligibility begins at age 65, so if you retire then and give up your group health plan at work, you’ll have coverage right away. But if your spouse gets his or her health insurance through you and your employer, and he or she is not yet eligible for Medicare, you’ll need to collectively figure out what to do about medical coverage. Though you can obtain insurance through COBRA, the cost can be prohibitive, and your maximum coverage period is generally 18 months. Buying insurance on the open market is also an option, but you might find yourself spending quite a substantial amount of money for coverage that’s mediocre at best.

Hot Medical Stocks To Invest In 2019: Jason Industries, Inc.(JASN)

Advisors’ Opinion:

  • [By Shane Hupp]

    PlayAGS (NYSE: AGS) and Jason Industries (NASDAQ:JASN) are both small-cap consumer discretionary companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, profitability, earnings and institutional ownership.

Hot Medical Stocks To Invest In 2019: Sage Therapeutics, Inc.(SAGE)

Advisors’ Opinion:

  • [By Maxx Chatsko]

    Shares of Sage Therapeutics (NASDAQ:SAGE) soared more than 20% today after the company announced that the U.S. Food and Drug Administration will allow an expedited development program for one of its most promising drug candidates.

  • [By Shane Hupp]

    SG Americas Securities LLC acquired a new position in SAGE Therapeutics Inc (NASDAQ:SAGE) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 5,233 shares of the biopharmaceutical company’s stock, valued at approximately $843,000.

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

Hot Medical Stocks To Invest In 2019: Hudson Technologies, Inc.(HDSN)

Advisors’ Opinion:

  • [By Lisa Levin]

    Hudson Technologies Inc. (NASDAQ: HDSN) was down, falling around 25 percent to $3.07 after the company reported downbeat Q1 earnings.

    Commodities

  • [By Shane Hupp]

    Hudson Technologies (NASDAQ:HDSN) released its quarterly earnings results on Wednesday. The industrial products company reported ($0.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.01 by ($0.03), Bloomberg Earnings reports. Hudson Technologies had a return on equity of 6.44% and a net margin of 1.64%. The business had revenue of $42.43 million during the quarter, compared to the consensus estimate of $45.88 million.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Hudson Technologies (HDSN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Hudson Technologies, Inc. (NASDAQ:HDSN) traded up 20.3% during trading on Thursday following insider buying activity. The company traded as high as $2.73 and last traded at $2.61. 2,803,817 shares changed hands during mid-day trading, an increase of 473% from the average session volume of 488,999 shares. The stock had previously closed at $2.17.

  • [By Lisa Levin]

    Hudson Technologies Inc. (NASDAQ: HDSN) was down, falling around 29 percent to $2.9199 after the company reported downbeat Q1 earnings.

    Commodities

Hot Medical Stocks To Invest In 2019: The Rubicon Project, Inc.(RUBI)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Rubicon Project (NYSE: RUBI) is one of 44 publicly-traded companies in the “Computer programming, data processing, & other computer related” industry, but how does it weigh in compared to its competitors? We will compare Rubicon Project to related companies based on the strength of its analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.

  • [By Max Byerly]

    Rubicon Project (NYSE:RUBI) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Wednesday.

  • [By Ethan Ryder]

    The Rubicon Project Inc (NYSE:RUBI) saw unusually-high trading volume on Wednesday . Approximately 1,541,600 shares traded hands during trading, an increase of 150% from the previous session’s volume of 615,518 shares.The stock last traded at $3.22 and had previously closed at $2.90.

Hot Medical Stocks To Invest In 2019: FibroGen, Inc(FGEN)

Advisors’ Opinion:

  • [By Ethan Ryder]

    FibroGen (NASDAQ:FGEN) Director Jorma Routti sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, May 9th. The shares were sold at an average price of $47.10, for a total transaction of $282,600.00. Following the completion of the transaction, the director now directly owns 133,840 shares in the company, valued at approximately $6,303,864. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on FibroGen (FGEN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *